Slides
Page 1
November 2, 2026 Third Quarter 2026 Financial Results and Business Update
Page 2
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. (“Syndax” or the “Company”), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax’s product candidates, the progress of regulatory submissions and approvals and subsequent commercialization and the potential use of Syndax’s product candidates to treat various cancer indications and fibrotic diseases, and Syndax’s expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical site activation rates or clinical trial enrollment rates that are lower than expected; changes in expected or existing competition; the impact of macroeconomic conditions (the Russia-Ukraine war, inflation, among others) on Syndax’s business and that of the third parties on which Syndax depends, including delaying or otherwise disrupting Syndax’s clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. New risks emerge from time to time. It is not possible for Syndax’s management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor , or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward- looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax’s expectations. 2
Page 3
Strong 3Q26 commercial growth and progress across our pipeline 31. Estimated peak annual U.S. net revenue potential is inclusive of anticipated frontline indications. Market share estimates based on prescription and claims data on file. y/y, year-over-year; q/q, quarter-over-quarter; Tx, treatment; HSCT, hematopoietic stem cell transplant • Dominant share of new patients and revenue for the class • 20% q/q increase in new patients and growing use post-HSCT • $2B+ peak annual net revenue expected in the U.S. alone1 $61M 3Q26 net revenue (+90% y/y) $67M 3Q26 net revenue (+47% y/y) • $23M in collaboration revenue to Syndax—a meaningful contribution to our bottom line • Collaboration revenue currently annualizing at $90M+ • Frontline (1L) trials of Revuforj and Niktimvo underway; positioned to be first to 1L AML with a menin inhibitor • Major presence planned at ASH, including new revumenib data across the acute leukemia Tx continuum • Two novel pipeline assets expected to enter the clinic in 2027 Poised to unlock significant value with two drugs with blockbuster potential and a differentiated pipeline Growing revenue from two medicines Advancing expansion opportunities
Page 4
Double-digit q/q growth in Revuforj net revenue, new patients, and TRx TRx, total prescriptions; HSCT, hematopoietic stem cell transplant; Tx, treatment; q/q, quarter-over-quarter ~300 new patient starts 3Q26 results $60.7M net revenue ~1,700 total prescriptions ~100% growth vs. 3Q25 ~13% growth vs. 2Q26 $0 $10 $20 $30 $40 $50 $60 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 90% growth vs. 3Q25 11% growth vs. 2Q26 Net revenue ($M) Approx. TRx Quarterly results 4 ~20% q/q growth Growth reflects strong uptake in two indications and a growing number of patients on Tx post-HSCT Seven consecutive quarters of double- digit q/q net revenue and TRx growth Dominant share of new patient starts for the class
Page 5
Revuforj’s strong growth potential supported by multiple evolving Tx dynamics 5 Continued use early in the R/R Tx paradigm and in combination Robust transplant rates observed in both R/R KMT2A and NPM1 % proceeding to HSCT % resuming Tx post-HSCT KMT2A ~50% ~60% NPM1 ~40% ~50% Growing adoption in R/R NPM1m AML ~40% of use in combo ~75% of use in 2L/3L of new 3Q26 patients were NPM1 patients ~50% >35% of 3Q26 net revenue from NPM1 business Estimates based on claims, prescription, and lab data on file.
Page 6
Syndax is well positioned to continue driving growth in both Revuforj indications 6 All covered lives includes all commercially covered lives plus Medicare and Medicaid lives. Excellent payer coverage with no meaningful barriers to access of all covered lives with formulary coverage for both Revuforj indications 99% Broad and expanding prescriber base of Tier 1+2 accounts activated >90% total accounts (+8% q/q growth) >620 Growing adoption in centers of all sizes
Page 7
Strong Niktimvo 3Q26 results driven by robust demand and solid persistency >300 3Q26 new patients ~6,350 3Q26 infusions administered Syndax records 50% of the Niktimvo net commercial profit, defined as net revenue (recorded by Incyte) minus the cost of sales and commercial expenses. $67.4M 3Q26 net revenue reported by INCY 47% growth vs. 3Q25 12% growth vs. 2Q26 $22.6M 3Q26 collaboration revenue to SNDX 63% growth vs. 3Q25 25% growth vs. 2Q26 Collaboration revenue currently annualizing at $90M+ 7
Page 8
Pioneering menin inhibition with an industry-leading integrated evidence generation plan 8Rev, revumenib; IC, intensive chemotherapy; 1L, frontline; R/R, relapsed or refractory; ven/aza, venetoclax and azacitidine; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation; gilt, gilteritinib Major presence planned for upcoming medical meetings New data expected in 4Q26 from: • 1L combo trials o BEAT AML o SAVE o 708 • MRD relapse study o INTERCEPT • Pre- and post- transplant setting • Real-world studies Revumenib (select acute leukemia trials) Ph 1 Ph 2 Ph 3 FDA ApprovedSetting Study Name Regimen NPM1m KMT2Ar NUP98r R/R AUGMENT-101 Rev mono ● ● AUGMENT-102 Rev + IC ● ● ● SAVE Rev + ven/oral HMA ● ● ● Borate study Rev + gilt in FLT3 co-mutated ● ● ● Post-HSCT Maintenance Ball study Rev mono ● ● MenTain Rev mono ● ● ● MRD clearance INTERCEPT Rev mono ● ● Break Through Cancer Rev + ven ● ● ● 1L Unfit for IC BEAT AML Rev + ven/aza ● ● SAVE Rev + ven/oral HMA ● ● ● EVOLVE-2 Rev + ven/aza ● ● Fit for IC 708 and NCI Rev + IC ● ● ● REVEAL-ND Rev + IC ● RAVEN Rev + ven/aza ●
Page 9
Advancing multiple programs and novel assets targeting high unmet needs 9 NSCLC, non-small cell lung cancer; MF, myelofibrosis; 1L, frontline + Multiple ongoing trials across the acute leukemia Tx continuum; positioned to be first to 1L AML SNDX-4321 Mutant-selective allosteric EGFR inhibitor for NSCLC IND submission expected by YE26; demonstration of monotherapy activity anticipated early 2028 Ph 1 initiation expected 4Q27, building on planned proof-of-principle trial of revumenib in MF Two ongoing combination trials with ruxolitinib or corticosteroids targeting 1L chronic GVHD FOUR INNOVATIVE ASSETS EXPECTED IN THE CLINIC IN 2027 Next-generation menin inhibitor for MF SNDX-62122 Life-cycle management Pipeline assets
Page 10
10 Strong financial position with growing revenue and a robust balance sheet Financial Summary ($ in millions) Three Months Ended Sept 30 2026 2025 Product revenue, net 60.7 32.0 Collaboration revenue, net 22.6 13.9 Total revenues 83.3 45.9 Cost of product sales (14.0) (2.1) Research & development (R&D) (67.5) (56.3) Selling, general and administrative (SG&A) (43.7) (44.9) Total operating expenses (125.2) (103.3) Other (expense) income, net (7.5) (3.3) Net loss (49.4) (60.7) Totals may not sum due to rounding; 1. Includes short- and long-term investments. AS OF 30 SEPT 2026: $551.1M in cash and equivalents1 90.0M shares outstanding 2026 R&D + SG&A EXPENSE GUIDANCE: $400M, excluding $50M in expected stock option expense On the road to profitability
Page 11
Positioned to unlock blockbuster opportunities and build long-term value 11 Proven ability to translate scientific discoveries into novel therapies, with three FDA approvals between two drugs and thousands of patients treated Fully integrated biotech with deep expertise and strong partnerships with leading researchers Two drugs with compelling expansion opportunities + two differentiated pipeline assets; strong patent protection into at least late 2030s1 Driving towards profitability with growing revenues; fully funded to advance late-stage trials and pipeline assets SOLID FINANCIAL POSITION TRACK RECORD OF SUCCESS WORLD-CLASS R&D CAPABILITIES MULTIPLE SHOTS ON GOAL 1. Patent protection into at least late 2030s for Revuforj and Niktimvo and at least 2040s for SNDX-4321 and SNDX-62122.
Page 12
12 Acute Leukemia • Advance global enrollment in pivotal 1L trials of revumenib • New 1L, maintenance, real-world, and MRD relapse data in 4Q26 + beyond • Publish R/R NUP98r data in 4Q26 and submit publication to clinical guidelines Myelofibrosis • Initiate Ph 1/2 proof-of-principle trial of revumenib in 4Q26; initial data 2H27 • Submit IND and initiate Ph 1 SNDX-62122 trial in 4Q27 Frontline Chronic GVHD • Topline Ph 2 axatilimab + ruxolitinib data at a medical meeting in 1Q27 • Topline Ph 3 axatilimab + corticosteroid data early 2028 EGFR-mutated NSCLC • Submit IND by YE 2026 • Initiate Ph 1 trial in 2027; initial data early 2028 Anticipated milestones Revuforj (revumenib) & SNDX-62122 SNDX-4321 Niktimvo (axatilimab-csfr) Multiple near-term catalysts and value-creating opportunities
Page 13
13 Sarah, diagnosed with R/R acute leukemia FUELED BY A PASSION FOR PATIENTS